secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-03-28T23:59:59+00:00
Accession:  0000950170-22-004778
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Bioworks FY2021 revenue $314M (+309% YoY); 2022 guidance $325-340M
-------------------------------------------------------------------------

- Full-year 2021 total revenue $314M, up 309% YoY; Foundry revenue $113M (+91%), Biosecurity $201M (exceeded $110M outlook).
- Added 31 new Cell Programs in 2021 (+72% YoY); 2022 guidance expects 60 new programs.
- Q4 2021 total revenue $148M vs $32M YoY; Adjusted EBITDA $1M vs $(51)M in prior year.
- GAAP loss from ops $(1.8)B including $1.7B catch-up stock comp; cash balance >$1.5B.
- Announced two tuck-in acquisitions in 2022: Project Beacon (COVID testing) and FGen (strain optimization).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022004778/0000950170-22-004778-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022004778/dna-20220328.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-004778

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer